Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TELA TELA Bio Inc
- Stocks
- Healthcare
- NASDAQ: TELA
Price (delayed)
$1.97
Market cap
$77.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.35
Enterprise value
$76.1M
TELA Bio Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company is
Highlights
TELA Bio's EPS has increased by 19% YoY
TELA's revenue is up by 13% year-on-year and by 2.8% since the previous quarter
The equity has declined by 36% since the previous quarter but it has grown by 26% year-on-year
The quick ratio is down by 20% since the previous quarter but it is up by 3.8% year-on-year
The company's net income fell by 15% QoQ and by 8% YoY
The gross margin is down by 3% year-on-year
Key stats
What are the main financial stats of TELA
Market
Valuations
Earnings
Shares outstanding
39.55M
Market cap
$77.92M
Enterprise value
$76.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.3
Price to sales (P/S)
1.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.07
Revenue
$71.22M
Gross profit
$47.66M
Operating income
-$39.76M
Net income
-$43.44M
EBIT
-$38.36M
EBITDA
-$37.31M
Free cash flow
-$37.65M
Per share
Balance sheet
Liquidity
EPS
-$1.35
EPS diluted
-$1.35
Free cash flow per share
-$0.83
Book value per share
$0.46
Revenue per share
$1.57
TBVPS
$1.67
Total assets
$77.25M
Total liabilities
$59.13M
Debt
$41.28M
Equity
$18.12M
Working capital
$53.21M
Debt to equity
2.28
Current ratio
4.22
Quick ratio
3.24
Net debt/EBITDA
0.05
Margins
Efficiency
Dividend
EBITDA margin
-52.4%
Gross margin
66.9%
Net margin
-61%
Operating margin
-55.8%
Return on assets
-62.7%
Return on equity
-402.5%
Return on invested capital
-66.8%
Return on capital employed
-63.2%
Return on sales
-53.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TELA stock price
How has the TELA Bio stock price performed over time
Intraday
6.49%
1 week
19.39%
1 month
33.11%
1 year
-61.67%
YTD
-34.77%
QTD
61.48%
Financial performance
How have TELA Bio's revenue and profit performed over time
Revenue
$71.22M
Gross profit
$47.66M
Operating income
-$39.76M
Net income
-$43.44M
Gross margin
66.9%
Net margin
-61%
The operating margin has grown by 22% YoY and by 7% from the previous quarter
The company's net income fell by 15% QoQ and by 8% YoY
TELA's revenue is up by 13% year-on-year and by 2.8% since the previous quarter
TELA Bio's net margin has decreased by 12% from the previous quarter but it has increased by 4.4% YoY
Price vs fundamentals
How does TELA's price correlate with its fundamentals
Growth
What is TELA Bio's growth rate over time
Valuation
What is TELA Bio stock price valuation
P/E
N/A
P/B
4.3
P/S
1.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.07
TELA Bio's EPS has increased by 19% YoY
The P/B is 65% less than the 5-year quarterly average of 12.2
The equity has declined by 36% since the previous quarter but it has grown by 26% year-on-year
TELA's price to sales (P/S) is 76% less than its 5-year quarterly average of 5.3 but 4.2% more than its last 4 quarters average of 1.2
TELA's revenue is up by 13% year-on-year and by 2.8% since the previous quarter
Efficiency
How efficient is TELA Bio business performance
TELA Bio's return on equity has shrunk by 159% YoY and by 4.9% QoQ
TELA's ROA is down by 29% year-on-year and by 13% since the previous quarter
TELA's ROIC is down by 18% QoQ and by 3.2% YoY
TELA Bio's ROS has decreased by 14% from the previous quarter but it has increased by 2.7% YoY
Dividends
What is TELA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TELA.
Financial health
How did TELA Bio financials performed over time
TELA's total assets is 31% more than its total liabilities
The quick ratio is down by 20% since the previous quarter but it is up by 3.8% year-on-year
The current ratio has contracted by 16% from the previous quarter but it has grown by 2.2% YoY
TELA Bio's debt is 128% more than its equity
TELA Bio's debt to equity has surged by 57% QoQ but it has decreased by 19% YoY
The equity has declined by 36% since the previous quarter but it has grown by 26% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.